2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

655. Multiple Myeloma: Cellular Therapies: Poster I

Program: Poster Abstract Session
Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Clinical Procedures, Emerging Technologies, Treatment Considerations, Biological Therapies, Bispecific Antibody Therapy, Chimeric Antigen Receptor, (CAR)-T Cell Therapies, Immunotherapy, Adverse Events, Clinical Practice (Health Services and Quality), Patient Safety, Quality Improvement, Diseases, Infectious Diseases, Lymphoid Malignancies, Lymphomas, Plasma Cell Disorders, B Cell Lymphoma, Research, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Real-World Evidence, Registries, Study Population, Human, Adult
PAPER

2285 A real-world analysis of clinical and systemic Barriers to CAR-T Therapy in multiple myeloma.

Sameeran Das, Mark A Fiala, PhD2, Mengmeng Ji, PhD, MBBS3, Shelbie Fishman4, Dionne Stalling5, Michael J. Slade, MD, MSCI6, Ravi Vij, MD, MBA7, Su-Hsin Chang, PhD8
1 Washington University School of Medicine, St. Louis, Missouri, United States
2 Washington University School of Medicine, St. Louis, Missouri, United States
3 Washington University School of Medicine, St. Louis, Missouri, United States
4 Washington University School of Medicine, St. Louis, Missouri, United States
5 Rare and Black, St. Louis, Missouri, United States
6 Washington University School of Medicine, St. Louis, Missouri, United States
7 Washington University School of Medicine, St. Louis, Missouri, United States
8 Washington University School of Medicine, St. Louis, Missouri, United States

Background: While chimeric antigen receptor T-cell (CAR-T) therapy has offered a promising route to manage relapsed/refractory multiple myeloma (MM), access remains limited. Patients have faced significant barriers, e.g. long waitlists, lengthy insurance authorizations, travel burdens, and manufacturing shortages. Using real-world data, this study characterizes the barriers encountered by MM patients who were considered for but did not receive CAR-T therapy.

Methods: We created a rules-based natural language processing (NLP) algorithm to review clinic notes and identify MM patients who were considered for CAR-T at an NCI-designated comprehensive cancer center. Among patients who did not undergo CAR-T, narrative summaries detailing the reason for non-receipt were created using chart review. The summaries were then coded into mutually exclusive categories: 1) physician-determined ineligibility at consultation; 2) clinical deterioration post initial consultation; 3) patient-directed refusal; 4) structural barriers (e.g., manufacturing availability, insurance issues); and 5) Indeterminate. We then performed a secondary analysis to characterize barriers that were related to social drivers of health (SDOH), which cut across the five categories. For example, lack of social support may have been a reason for physician-determined ineligibility or patient-directed refusal. Finally, we performed logistic regression to determine if patient age, sex, race/ethnicity, or socioeconomic disadvantage, as measured by the Area Deprivation Index (ADI), a tool that ranks neighborhoods using income, education, employment, and housing data, were associated with CAR-T receipt.  

Results: The NLP algorithm identified 717 unique MM patients. After screening, 242 were excluded as CAR-T was listed as a possible future treatment without active consideration, and 7 were excluded as CAR-T was considered for treatment of a comorbid malignancy rather than MM. In total, 228 had undergone CAR-T, and 4 were in active workup at the time of data collection.

Of the 236 patients who had not undergone CAR-T or were not in active workup, 40.3% (n = 95) were determined to be ineligible at the time of initial CAR-T consultation. Another 24.6% (n = 58) were deemed potential candidates, but the patient declined the procedure. Following initial eligibility determination, 18.6% (n = 44) had clinical deterioration and could not proceed, while another 10.2% (n = 24) could not proceed due to a structural barrier. In total, 6.4% (n = 15) of patients did not have a documented reason why CAR-T was not performed. Barriers related to SDOH were documented in 38 of 236 patients (16.1%), which consisted of social support deficits (n = 14), insurance or coverage barriers (n = 12), geographic or travel burden (n = 7), and financial or employment constraints (n = 5).

Multivariable analysis showed that each year of increasing age was associated with a 3% decrease in odds of receiving a CAR-T (aOR 0.97; 95% CI 0.95-0.99; p = 0.006) and each 10-point increase in ADI, signifying greater disadvantage, was associated with a 9% decrease in odds of CAR-T (aOR 0.91; 95% CI 0.84-0.99; p = 0.030). Patient sex and race/ethnicity were not statistically associated with CAR-T receipt.

Conclusion: Significant attrition in the MM CAR-T pipeline is driven by clinical and patient-level factors—namely ineligibility, patient refusal, clinical deterioration, and structural barriers. Moreover, both our quantitative and qualitative data suggest that socioeconomic disadvantage actively limits access. Interventions to improve CAR-T access should include earlier patient identification to outpace clinical deterioration, improved patient education to address the high rate of refusal, and comprehensive navigation to overcome the geographic and financial barriers disproportionately affecting vulnerable populations.

Sameeran Das: No relevant conflicts of interest to declare.